{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:22:31Z","timestamp":1785813751364,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipoproteinemias can be classified by their distinct lipoprotein patterns, which helps determine atherosclerotic cardiovascular disease (ASCVD) risk and directs lipid management but this has required advanced laboratory testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop a new algorithm for classifying lipoprotein disorders that only relies on the standard lipid panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Lipid thresholds for defining the different lipoprotein phenotypes were derived for Non-High-Density Lipoprotein-Cholesterol (NonHDL-C) and Triglycerides (TG) to be concordant when possible with the current US Multi-Society guidelines for blood cholesterol management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The new classification method categorizes patients into all the classical Fredrickson-like phenotypes except for Type III dysbetalipoproteinemia. In addition, a new hypolipidemic phenotype (Type VI) due to genetic mutations in apoB-metabolism is described. The validity of the new algorithm was confirmed by lipid analysis by NMR (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200911,365) and by concordance with classification by agarose gel electrophoresis\/beta-quantification (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20095504). Furthermore, based on the Atherosclerosis Risk in Communities (ARIC) cohort (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200914,742), the lipoprotein phenotypes differ in their association with ASCVD (TypeV&gt;IIb\u2009&gt;\u2009IVb\u2009&gt;\u2009IIa\u2009&gt;\u2009IVa\u2009&gt;\u2009normolipidemic) and can be used prognostically as risk enhancer conditions in the management of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We describe a clinically useful lipoprotein phenotyping system that is only dependent upon the standard lipid panel. It, therefore, can be easily implemented for increasing compliance with current guidelines and for improving the care of patients at risk for ASCVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-021-01585-8","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T11:02:27Z","timestamp":1638010947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A new phenotypic classification system for dyslipidemias based on the standard lipid panel"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-250X","authenticated-orcid":false,"given":"Maureen","family":"Sampson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami A.","family":"Ballout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wolska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Meeusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Fatica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Otvos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shamburek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios K.","family":"Karathanasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"issue":"25","key":"1585_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"key":"1585_CR2","doi-asserted-by":"crossref","unstructured":"Fredrickson, D.S., R.I. Levy, and R.S. Lees, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med, 1967. 276(1): p. 34\u201342 contd.","DOI":"10.1056\/NEJM196701052760107"},{"key":"1585_CR3","doi-asserted-by":"crossref","unstructured":"Fredrickson, D.S., R.I. Levy, and R.S. Lees, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med, 1967. 276(2): p. 94\u2013103 contd.","DOI":"10.1056\/NEJM196701122760206"},{"key":"1585_CR4","doi-asserted-by":"crossref","unstructured":"Fredrickson, D.S., R.I. Levy, and R.S. Lees, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med, 1967. 276(3): p. 148\u201356 contd.","DOI":"10.1056\/NEJM196701192760305"},{"key":"1585_CR5","doi-asserted-by":"crossref","unstructured":"Fredrickson, D.S., R.I. Levy, and R.S. Lees, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med, 1967. 276(4): p. 215\u201325 contd.","DOI":"10.1056\/NEJM196701262760406"},{"key":"1585_CR6","doi-asserted-by":"crossref","unstructured":"Fredrickson, D.S., R.I. Levy, and R.S. Lees, Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med, 1967. 276(5): p. 273\u201381 concl.","DOI":"10.1056\/NEJM196702022760507"},{"issue":"1","key":"1585_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jacl.2016.12.005","volume":"11","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Najera SD, Hegele RA. Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. J Clin Lipidol. 2017;11(1):294\u20136.","journal-title":"J Clin Lipidol"},{"issue":"9","key":"1585_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11883-014-0440-2","volume":"16","author":"PN Hopkins","year":"2014","unstructured":"Hopkins PN, Brinton EA, Nanjee MN. Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep. 2014;16(9):440.","journal-title":"Curr Atheroscler Rep"},{"issue":"4 Suppl","key":"1585_CR9","first-page":"III1","volume":"87","author":"DS Fredrickson","year":"1993","unstructured":"Fredrickson DS. Phenotyping. On reaching base camp (1950-1975). Circulation. 1993;87(4 Suppl):III1\u201315.","journal-title":"Circulation"},{"issue":"4","key":"1585_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jacl.2007.07.006","volume":"1","author":"A Sniderman","year":"2007","unstructured":"Sniderman A, et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol. 2007;1(4):256\u201363.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1585_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrendo.2010.50","volume":"6","author":"A Sniderman","year":"2010","unstructured":"Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010;6(6):335\u201346.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1585_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ecl.2015.09.012","volume":"45","author":"EA Brinton","year":"2016","unstructured":"Brinton EA. Management of Hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. Endocrinol Metab Clin N Am. 2016;45(1):185\u2013204.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"1","key":"1585_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"1585_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1585_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","volume":"5","author":"M Sampson","year":"2020","unstructured":"Sampson M, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with Normolipidemia and\/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540\u20138.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1585_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.mol.0000137220.39031.3b","volume":"15","author":"AD Sniderman","year":"2004","unstructured":"Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol. 2004;15(4):433\u20138.","journal-title":"Curr Opin Lipidol"},{"key":"1585_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2018.11.001","volume":"282","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Robinson JG. ApoB in clinical care: pro and con. Atherosclerosis. 2019;282:169\u201375.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1585_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12944-020-01424-2","volume":"19","author":"E Garcia","year":"2020","unstructured":"Garcia E, et al. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Lipids Health Dis. 2020;19(1):247.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"1585_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","volume":"26","author":"EJ Jeyarajah","year":"2006","unstructured":"Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847\u201370.","journal-title":"Clin Lab Med"},{"issue":"3","key":"1585_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","volume":"109","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433\u20138.","journal-title":"Circulation"},{"issue":"6","key":"1585_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12328-018-0881-1","volume":"11","author":"P Rawla","year":"2018","unstructured":"Rawla P, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clin J Gastroenterol. 2018;11(6):441\u20138.","journal-title":"Clin J Gastroenterol"},{"issue":"2","key":"1585_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","volume":"65","author":"SEJ Hansen","year":"2019","unstructured":"Hansen SEJ, et al. Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem. 2019;65(2):321\u201332.","journal-title":"Clin Chem"},{"key":"1585_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fpubh.2017.00252","volume":"5","author":"G Migliara","year":"2017","unstructured":"Migliara G, et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Front Public Health. 2017;5:252.","journal-title":"Front Public Health"},{"key":"1585_CR24","unstructured":"Goff, D.C., Jr., et al., 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J am Coll Cardiol, 2014. 63(25 Pt B): p. 2935-2959."},{"issue":"1","key":"1585_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00004836-199002000-00024","volume":"12","author":"J Lenaerts","year":"1990","unstructured":"Lenaerts J, et al. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature. J Clin Gastroenterol. 1990;12(1):93\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"1585_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/MOL.0000000000000270","volume":"27","author":"AJ Brahm","year":"2016","unstructured":"Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. Curr Opin Lipidol. 2016;27(2):131\u201340.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"1585_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","volume":"25","author":"FK Welty","year":"2014","unstructured":"Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014;25(3):161\u20138.","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"1585_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11883-014-0423-3","volume":"16","author":"AJ Hooper","year":"2014","unstructured":"Hooper AJ, Burnett JR. Update on primary hypobetalipoproteinemia. Curr Atheroscler Rep. 2014;16(7):423.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1585_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.17219\/acem\/67968","volume":"27","author":"Z Chowaniec","year":"2018","unstructured":"Chowaniec Z, Skoczynska A. Plasma lipid transfer proteins: the role of PLTP and CETP in atherogenesis. Adv Clin Exp Med. 2018;27(3):429\u201336.","journal-title":"Adv Clin Exp Med"},{"issue":"9","key":"1585_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11883-014-0437-x","volume":"16","author":"X Prieur","year":"2014","unstructured":"Prieur X, et al. Congenital lipodystrophies and dyslipidemias. Curr Atheroscler Rep. 2014;16(9):437.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"1585_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1373\/clinchem.2018.292425","volume":"65","author":"CS Boot","year":"2019","unstructured":"Boot CS, et al. Evaluation of the non-HDL cholesterol to Apolipoprotein B ratio as a screening test for Dysbetalipoproteinemia. Clin Chem. 2019;65(2):313\u201320.","journal-title":"Clin Chem"},{"key":"1585_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2012.09.010","volume":"414","author":"S Hirayama","year":"2012","unstructured":"Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215\u201324.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"1585_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cjca.2017.12.007","volume":"34","author":"P Stahel","year":"2018","unstructured":"Stahel P, et al. The Atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2018;34(5):595\u2013604.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1585_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.10702","volume":"19","author":"T Gotoda","year":"2012","unstructured":"Gotoda T, et al. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19(1):1\u201312.","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"1585_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/clp.11.24","volume":"6","author":"DR Sullivan","year":"2011","unstructured":"Sullivan DR, Lewis B. A classification of lipoprotein disorders:implications for clinical management. Clinical Lipidology. 2011;6(3):327\u201338.","journal-title":"Clinical Lipidology"},{"issue":"5","key":"1585_CR36","first-page":"224","volume":"70","author":"OY Bello-Chavolla","year":"2018","unstructured":"Bello-Chavolla OY, et al. Familial combined hyperlipidemia: current knowledge, perspectives, and controversies. Rev Investig Clin. 2018;70(5):224\u201336.","journal-title":"Rev Investig Clin"},{"issue":"8","key":"1585_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3 Suppl","key":"1585_CR38","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1\u20138.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1585_CR39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","volume":"72","author":"AC Sturm","year":"2018","unstructured":"Sturm AC, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72(6):662\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"1585_CR40","volume-title":"And S","author":"J Paik","year":"2019","unstructured":"Paik J. And S. First Global Approval. Drugs: Duggan, Volanesorsen; 2019."},{"issue":"6","key":"1585_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11886-019-1130-z","volume":"21","author":"M Sharifi","year":"2019","unstructured":"Sharifi M, et al. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019;21(6):43.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"1585_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0025-7125(16)30179-1","volume":"78","author":"NJ Stone","year":"1994","unstructured":"Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994;78(1):117\u201341.","journal-title":"Med Clin North Am"},{"issue":"2","key":"1585_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pathol.2018.10.014","volume":"51","author":"AJ Berberich","year":"2019","unstructured":"Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. Pathology. 2019;51(2):184\u201392.","journal-title":"Pathology"},{"issue":"8","key":"1585_CR44","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/js.2019-00129","volume":"3","author":"MI Esparza","year":"2019","unstructured":"Esparza MI, et al. Very severe hypertriglyceridemia in a large US County health care system: associated conditions and management. J Endocr Soc. 2019;3(8):1595\u2013607.","journal-title":"J Endocr Soc"},{"issue":"2","key":"1585_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MOL.0000000000000482","volume":"29","author":"JS Dron","year":"2018","unstructured":"Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol. 2018;29(2):133\u201343.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"1585_CR46","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu5030981","volume":"5","author":"A Brahm","year":"2013","unstructured":"Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013;5(3):981\u20131001.","journal-title":"Nutrients"},{"key":"1585_CR47","doi-asserted-by":"crossref","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2019.","DOI":"10.1016\/j.tcm.2019.03.001"},{"issue":"2","key":"1585_CR48","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.atherosclerosis.2014.09.029","volume":"237","author":"PP Toth","year":"2014","unstructured":"Toth PP, et al. Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis. 2014;237(2):790\u20137.","journal-title":"Atherosclerosis"},{"key":"1585_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1476-511X-10-157","volume":"10","author":"S Sandhu","year":"2011","unstructured":"Sandhu S, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011;10:157.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"1585_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11886-013-0391-1","volume":"15","author":"J Barnett","year":"2013","unstructured":"Barnett J, Viljoen A, Wierzbicki AS. The need for combination drug therapies in patients with complex dyslipidemia. Curr Cardiol Rep. 2013;15(8):391.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"1585_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3909\/ricm0775","volume":"15","author":"KE Watson","year":"2014","unstructured":"Watson KE, et al. Advanced lipid testing: when, why, and in whom? Rev Cardiovasc Med. 2014;15(4):310\u20137 quiz 318-9.","journal-title":"Rev Cardiovasc Med"},{"issue":"2","key":"1585_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","volume":"5","author":"JD Otvos","year":"2011","unstructured":"Otvos JD, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105\u201313.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1585_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352\u201362.","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"1585_CR54","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292\u2013333.","journal-title":"Circulation"},{"issue":"4","key":"1585_CR55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310\u201320.","journal-title":"Curr Opin Lipidol"},{"issue":"23","key":"1585_CR56","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20136.","journal-title":"N Engl J Med"},{"key":"1585_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","volume":"267","author":"A Wolska","year":"2017","unstructured":"Wolska A, et al. Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis. 2017;267:49\u201360.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1585_CR58","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860\u201372.","journal-title":"J Clin Lipidol"},{"issue":"24","key":"1585_CR59","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"A-H Investigators","year":"2011","unstructured":"Investigators A-H, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"3","key":"1585_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"Group, H.T.C","year":"2014","unstructured":"Group, H.T.C, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"9943","key":"1585_CR61","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626\u201335.","journal-title":"Lancet"},{"issue":"1","key":"1585_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/clp.10.84","volume":"6","author":"M Elam","year":"2011","unstructured":"Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9\u201320.","journal-title":"Clin Lipidol"},{"key":"1585_CR63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/VHRM.S104369","volume":"12","author":"PP Toth","year":"2016","unstructured":"Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171\u201383.","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"1585_CR64","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, et al. Association of Triglyceride-Lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u201373.","journal-title":"JAMA"},{"key":"1585_CR65","first-page":"CD009753","volume":"11","author":"T Jakob","year":"2016","unstructured":"Jakob T, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01585-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01585-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01585-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:07:56Z","timestamp":1675951676000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01585-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01585-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-923991\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research under this study was considered non-human subject research and was exempted by the NIH-IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed final manuscript and given consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests. The following disclosures apply: ATR reports research support (CRADA) to his institution from AstraZeneca, Corvidia Therapeutics and Hartis Pharmaceuticals. RSR reports research support to his institution from Amgen, Novartis and Regeneron; serves on advisory boards for Amgen, C5, CVS Caremark, Novartis. Regneron and 89 Bio; receives honoraria for non-commercial educational activities from Amgen, Kowa, and Regeneron; has stock ownership in MediMergent LLC; and receives royalties from Wolters Kluwwer (UptoDate). None of the other authors have disclosures to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}